ChromaDex Corporation
CDXCDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
CHR-2797 (tosedostat): Aminopeptidase inhibitor
Acute Myeloid Leukemia
Tosedostat
Acute Myeloid Leukemia
Nicotinamide riboside
Inflammation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CHR-2797 (tosedostat): Aminopeptidase inhibitor | Phase 2 | Acute Myeloid Leukemia | - | - |
Tosedostat | Phase 2 | Acute Myeloid Leukemia | - | - |
Nicotinamide riboside | Phase 2 | Inflammation | - | - |
Frequently asked questions
What is in ChromaDex Corporation's drug pipeline?→
CatalystAlert tracks 3 drug candidates in ChromaDex Corporation's (CDXC) pipeline across Phase 2. Its lead program is CHR-2797 (tosedostat): Aminopeptidase inhibitor (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ChromaDex Corporation's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ChromaDex Corporation (CDXC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CDXC biotech catalysts?→
Add CDXC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ChromaDex Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.